Study Condition(s): Soft Tissue Sarcoma

A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Study Alias: JGDJ

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02451943 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The main purpose of this study is to evaluate the efficacy of the combination of doxorubicin plus the study drug known as olaratumab versus doxorubicin plus placebo in participants with advanced or metastatic soft tissue sarcoma.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18+ years

Time Commitment

Your participation in this trial could last >8 months, depending on how you and your tumor respond
  • Participant must have confirmed diagnosis of advanced unresectable or metastatic soft tissue sarcoma, that is not treatable with surgery or radiotherapy

  • Participant must consent to provide archived formalin-fixed paraffin embedded (FFPE) tumor tissue or undergo a pre-treatment re-biopsy of primary or metastatic tumor tissue

  • Participant must not have any abnormal function of the heart (cardiac dysfunction)

  • Participant must not have any planned or elective surgery

  • Participant must not have prior treatment with olaratumab, doxorubicin, epirubicin, idarubicin, and/or other anthracyclines and anthracenediones

  • Participant must not have had prior radiotherapy of the mediastinal/pericardial area or whole pelvis radiation

  • Female participant must not be pregnant or breastfeeding. Females of child-bearing potential and males must agree to use highly effective contraceptive during the trial and up to 3 months following the last dose of study drug

Where to Participate

130 locations are currently available of 136 planned
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.